Update of data from the world apheresis association (WAA) registry
Jazyk angličtina Země Velká Británie, Anglie Médium print-electronic
Typ dokumentu časopisecké články, přehledy
PubMed
40328001
DOI
10.1016/j.transci.2025.104132
PII: S1473-0502(25)00066-7
Knihovny.cz E-zdroje
- Klíčová slova
- Adverse events, Apheresis, Fluid replacement, Risks,
- MeSH
- lidé MeSH
- registrace * MeSH
- separace krevních složek * škodlivé účinky metody MeSH
- Check Tag
- lidé MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- přehledy MeSH
The WAA registry has been active since 2002. It allows bed side registration of safety and efficacy data. The data each center enters is accessible for its own use but also used for merged analysis. Most types of procedures are represented. Treatments of many severe diseases as well as the collection of autologous and donor cells for therapeutic use especially in oncologic diseases are recorded. Previous reports have shown a successive reduction in adverse events (AE) over the years. The aim of the present report is to update data of the risk for AE during the years from 2013 to Oct 2024. Contributions of 44 centers from 20 countries were analysed. Over these years, more than 169,000 apheresis procedures have been registered in more than 26,000 patients. During the study period the mean incidence of AE, merged for all types of procedures, was 1.6 /100 procedures for mild, 2.0/100 for moderate and 0.20/100 for severe AE, and reduced since 2013. Since 2002, death due to apheresis could not be excluded in one patient. There was an increased risk of hypotension during apheresis in patients with neurological diagnoses (ICD-10 chapter G) versus those with diseases of the musculoskeletal or connective tissue (ICD-10 chapter M) and vice versa for urticaria and tingling. In conclusion, the present data show the risk for various degrees of AE in apheresis procedures. Many patients suffer from severe illness and apheresis is often offered as a rescue therapy. Although the risk of death due to the apheresis procedure is extremely rare the concomitant severe disease itself poses a risk for severe events.
Apheresis and Cell Therapy Unit Concord Repatriation General Hospital Concord Australia
Apheresis Department Institute of Hematology and Blood Transfusion Prague Czech Republic
Blood Centre University Hospital Ostrava Czech Republic
Dep of Immunology and Transfusion Medicine Akershus University Hospital Lorenskog Norway
Dep of Pathology M P Shah Hospital Nairobi Kenya
Department of Clinical Immunology and Transfusion medicine Skåne University Hospital Lund Sweden
Department of Public Health and Clinical Medicine Umea University Umea Sweden
Dept Anesthesiology and Intensive Care Academic Hospital Paramaribo Suriname
Pediatric Hematology Oncology Tzu Chi Hospital Jakarta Indonesia
St Anna Kinderspital University Hospital Vienna Austria
Therapeutic Apheresis Unit Vilnius University Hospital Santariskiu clinics Vilnius Lithuania
Unit of Transfusion Medicine of Sanquin Blood Supply Sanquin Blood Supply Foundation the Netherlands
Citace poskytuje Crossref.org